Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06077110
Other study ID # RG214257
Secondary ID RARUR000125
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2023
Est. completion date March 2027

Study information

Verified date October 2023
Source The University of New South Wales
Contact Shuang Liang, PhD
Phone +61 2 9348 1126
Email shuang.liang4@unsw.edu.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to drive integration of precision medicine into routine oncology healthcare. It is hoped that this research will not only optimise the newly established P-OMICs-flow model of care within The Prince of Wales Hospital, but also prime it for use within other health care sites. The multidisciplinary team will work to achieve the following three objectives: 1. Co-design a clinic, implementation platform and suite of outcome measures to optimise P-OMICs-flow (Phase 1) 2. Test the implementation, service-, clinical, and cost-effectiveness of P-OMICs-flow (Phase 2) 3. Develop and pilot test a P-OMICs-flow scale-up model and toolkit (Phase 3) A mixed-methods approach will be used to develop and evaluate an implementation platform to support the integration of precision medicine into the routine oncology setting at a single hospital site. In the first study phase, interviews and focus-groups will be used to develop the implementation platform, which involves a co-designed model of care supported by a Learning Health System. A Type II Hybrid effectiveness-implementation trial design will then be used to test the implementation, clinical, and cost-effectiveness of the P-OMICs-flow model of care (phase 2). A combination of patient surveys and interviews will be used to measure patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs); stakeholder and patient interviews, surveys and focus-groups will be used to measure implementation outcomes; and cost data will be collected to inform an economic evaluation. These data will be collected at various stages of implementation to evaluate the effectiveness of the P-OMICs-flow model of care over time. In the final study phase (phase 3), a scale-up model will be developed to support implementation of the new model of care across a wider range of clinical contexts. (Phase 3 will be detailed in a separate ethics amendment) It is hoped that this research will not only optimise the newly established model of care within The Prince of Wales Hospital, but also prime it for use within other health care sites.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 300
Est. completion date March 2027
Est. primary completion date January 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - have been referred to the P-OMICs-flow clinic at POWH - speak English - are aged 18 years or over - are able to provide informed consent Exclusion Criteria: - aged under 18 years - non-English speaking - are unable to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
P-OMICs-flow services
The Service Intervention is the P-OMICs-flow clinic being delivered at The Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The University of New South Wales

Outcome

Type Measure Description Time frame Safety issue
Primary Implementation Outcomes appropriateness (e.g., perceived fit); qualitative measurement collected via interviews/focus groups/questionnaires 3 months post-referral
Primary Implementation Outcomes acceptability (clinician satisfaction); qualitative measurement collected via interviews/focus groups/questionnaires 3 months post-referral
Primary Implementation Outcomes feasibility; qualitative measurement collected via interviews/focus groups/questionnaires 3 months post-referral
Primary Implementation Outcomes adoption (e.g., telehealth uptake); qualitative measurement collected via interviews/focus groups/questionnaires 3 months post-referral
Primary Implementation Outcomes fidelity (care model adopted as intended); qualitative measurement collected via interviews/focus groups/questionnaires 3 months post-referral
Primary Implementation Outcomes cost (e.g., immediate versus ongoing implementation resource); qualitative measurement collected via interviews/focus groups/questionnaires 3 months post-referral
Primary Implementation Outcomes penetration (e.g., research enrolment numbers including culturally and linguistically diverse, remote/regional); qualitative measurement collected via interviews/focus groups/questionnaires 3 months post-referral
Primary Implementation Outcomes sustainability [industry engagement, grant support; clinical trial & access options, research links (e.g., sub-studies) generated]; qualitative measurement collected via interviews/focus groups/questionnaires 3 months post-referral
Primary Service Outcomes Upstream indicators of clinical effectiveness: intervals between time from referral to treatment; captured via audit data; measured in days; a smaller value indicates a preferred outcome. 3 months post-referral
Primary Service Outcomes Upstream indicators of clinical effectiveness that include: uptake of precision oncology treatment recommendations; captured via audit data; measured in percentages; a higher value indicates a preferred outcome. 3 months post-referral
Primary Service Outcomes Upstream indicators of clinical effectiveness that include: time from identification of germline research result to familial cancer clinic referral; captured via audit data, measured in days; a smaller value indicates a preferred outcome. 3 months post-referral
Primary Service Outcomes Upstream indicators of clinical effectiveness that include: time from identification of germline research result to clinical confirmation; captured via audit data, measured in days; a smaller value indicates a preferred outcome. 3 months post-referral
Primary Clinical Outcomes Patient reported experience of coordinated care; collected via questionnaires adapted for the precision medicine context; measured as ratings; a higher rating indicates a preferred outcome. 3 months post-referral
Secondary Clinical Outcome: Quality of life improvement (EQ-5D-5L, EuroQol-5 Dimension-5 Level) Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). There are 3,125 possible health states defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health). 3, 6, 9 months post-referral
Secondary Clinical Outcome: Views and attitudes (patient-perceived benefits and drawbacks of process and care model), result return preferences, knowledge, perceived importance of genomic profiling qualitative measures captured via interviews/questionnaires 3, 6, 9 months post-referral
Secondary Clinical Outcome: Psychological outcomes (e.g., anxiety and depression, coping with uncertainty) qualitative measures captured via interviews/questionnaires 3, 6, 9 months post-referral
Secondary Clinical Outcome: Decisional outcomes (e.g., decisional regret regarding personalised treatment, decisional satisfaction) qualitative measures captured via interviews/questionnaires 3, 6, 9 months post-referral
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients